These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25287898)

  • 21. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
    Iwanami J; Mogi M; Tsukuda K; Wang XL; Nakaoka H; Ohshima K; Chisaka T; Bai HY; Kanno H; Min LJ; Horiuchi M
    Hypertens Res; 2014 Jul; 37(7):616-20. PubMed ID: 24599018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
    Fliser D; Wagner KK; Loos A; Tsikas D; Haller H
    J Am Soc Nephrol; 2005 Apr; 16(4):1135-40. PubMed ID: 15716329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiproteinuric effect of olmesartan in patients with IgA nephropathy.
    Tomino Y; Kawamura T; Kimura K; Endoh M; Hosoya T; Horikoshi S; Utsunomiya Y; Yasuda T; Toyoda M; Tsuge T; Kaneko K
    J Nephrol; 2009; 22(2):224-31. PubMed ID: 19384840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.
    Suzuki R; Honda H; Niikura K; Akizawa T
    Clin Exp Hypertens; 2012; 34(2):125-31. PubMed ID: 21967019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.
    Jo F; Morimoto S; Nakahigashi M; Kusabe M; Someya K; Morita T; Jo H; Imada T; Kosaki A; Toyoda N; Nishikawa M; Iwasaka T
    Kidney Blood Press Res; 2011; 34(6):418-23. PubMed ID: 21709422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
    Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
    Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
    Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.
    Ohnishi K; Murase M; Nakano D; Pelisch N; Hitomi H; Kobori H; Morimoto S; Mori H; Masaki T; Ohmori K; Kohno M; Ichihara A; Nishiyama A
    J Pharmacol Sci; 2013; 122(2):103-8. PubMed ID: 23698111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.
    Utsumi K; Yasuda F; Watanabe Y; Higo S; Hirama A; Fujita E; Ueda K; Mii A; Kaneko T; Mishina M; Iino Y; Katayama Y
    Clin Chim Acta; 2012 Jan; 413(1-2):348-9. PubMed ID: 21983097
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
    Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes.
    Gutta S; Grobe N; Kumbaji M; Osman H; Saklayen M; Li G; Elased KM
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F263-F274. PubMed ID: 29561187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes.
    Tikellis C; Brown R; Head GA; Cooper ME; Thomas MC
    Am J Physiol Renal Physiol; 2014 Apr; 306(7):F773-80. PubMed ID: 24477684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.